Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma
Clinical trial NCT03677154 · COMPLETED
Trial details
- NCT number
- NCT03677154
- Sponsor
- Hoffmann-La Roche
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-05-23
- Primary completion
- 2025-08-07
- Enrollment
- 188
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.